Allowable Total Error Table
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
11-Deoxycortisol | 30 nmol/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
11-Desoxycortisol | S- | 27.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
17-Hydroxyprogesterone | S- | 30.2% | 5 BV | |
17-Hydroxyprogesterone | 3 nmol/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
5'-Hidroxiindolacetate, concentration, 2 | U- | 26.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
5'Nucleotidase | S- | 26.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
5HIAA | 20 umol/day, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
a-Amylase | S- | 15.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
a-Amylase (pancreatic) | S- | 17.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
a-Amylase concentration, random | U- | 103.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
a-Tocopherol | S- | 16.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
A/C Ratio | 2.5 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
a1-Acid Glycoprotein | S- | 16.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
a1-Antichymotrypsin | S- | 16.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
a1-Antitrypsin | S- | 9.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
a1-Globulins | S- | 15.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
a1-Microglobulin, concentration, first m | U- | 43.9% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
a2-Globulins | S- | 12.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
a2-Macroglobulin | S- | 7.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
a2-Microglobulin output, overnight | U- | 34.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Acetaminophen | 25% | 2 WLSH | ||
Acetaminophen | +/- 15% | 3 NYS | ||
Acetaminophen | Abbott AxSym | 3 SD | 4 CAP | |
Acetaminophen | 2.5 mg/mL or 25% | 6 AAB | ||
Acetaminophen | 20% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Acetone | 25% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Acid Phos(Pros) | 1.5 U/L & ug/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Acid Phos(Total) | 1.5 U/L & ug/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Acid phosphatase | S- | 10.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Acid phosphatase tartrate resistent | S- | 13.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
ACTH | 2.0 pmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Activated Clotting Time | 20% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Activated Clotting Time (ACT) | 2 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Activated Partial Thrombo Time | 15% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Activated partial thromboplastine time | P- | 4.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Active Renin | 1.0 uU/mL, 25% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Adenosine deaminase | S- | 16.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Adrenaline | 50 nmol/day, 33% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
AFP | Centaur | 3 SD | 4 CAP | |
AFP | 5 kIU/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
AFP (Amniotic Fluid) | +/- 3 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
AFP (Maternal Sera) | +/- 3 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
AFP, Amniotic Fluid | Centaur | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
AFP-Tumor (Chiron) | Centaur | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
AFPTM | +/- 3 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alanine aminotransferase | S- | 32.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alanine Aminotransferase | 20% | 6 AAB | ||
Alanine Aminotransferase | 35% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alanine aminotransferase (ALT, SGPT) | +/- 20% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Albumin | +/- 10% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Albumin | AU640 | 10% | 4 CAP | |
Albumin | S- | 3.9% | 5 BV | |
Albumin | 2.0 g/L, 10% | 7 RCPA | ||
Albumin | 10% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Albumin, concentration, first morning | U- | 46.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Albumin-Blood | BNII | 20% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Albumin-CSF | BNII | 20% | 4 CAP | |
Albumin-CSF | CSF | 0.10 g/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Albumin-Urine | U- | 0.1 g/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alcohol | 2.2 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alcohol (Ethanol), Urine | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alcohol, blood | +/- 25% | 1 CLIA, 2 WLSH, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alcohol, Serum | 25% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alcohol,blood | +/- 10% | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Aldosterone | S- | 36.7% | 5 BV | |
Aldosterone | 75.0 pmol/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Aldosterone, concentration | U- | 39.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alk Phos | AU640 | 30% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alkaline Phosphatase | 30% | 6 AAB | ||
Alkaline Phosphatase | 15 U/L, 15% | 7 RCPA | ||
Alkaline Phosphatase | 30% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alkaline phosphatase | +/- 30% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Alkaline phosphatase | S- | 11.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alkaline phosphatase, bone isoform | S- | 14.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alpha 1 Antitrypsin | BNII | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alpha fetoprotein (Prenatal screen) | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alpha-1 antitrypsin | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alpha-1-Antitrypsin | 3SD | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Alpha-fetoprotein | +/- 3 SD | 1 CLIA, 2 WLSH | ||
Alpha-fetoprotein | 5 kIU/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
ALT | AU640 | 20% | 4 CAP | |
ALT | 8 U/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Amikacin | 25% | 2 WLSH | ||
Amikacin | 2.0 mg/L, 10% | 7 RCPA | ||
Amikacin | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Amiodarone | 0.2 umol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Amitriptyline | 10 umol/L, 10% | 7 RCPA | ||
Amitriptyline | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ammonia | 2.5 SD | 2 WLSH | ||
Ammonia | AU640 | not evaluated | 4 CAP | |
Ammonia | 3 umol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ammonia, output | U- | 29.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ammonia, Serum | 10 umol/L or 5% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Amphetamine | Abbott AxSym | 80% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Amphetamines | Pos/Neg | 2 WLSH | ||
Amphetamines | 20% or 2 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Amphetamines, qualitative | Presence or Absence | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Amylase | +/- 30% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Amylase | AU640 | 30% | 4 CAP | |
Amylase | 15 U/L, 15% | 7 RCPA | ||
Amylase | 20% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Amylase -urine | U- | 30% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Amylase, urine | U- | AU640 | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Androstendione | S- | 22.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Androstenedione | 2.0 nmol/L | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Angiotensin converting enzyme | P- | 17.9% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Anti-CMV | Positive or Negative | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Anti-Human Immunodeficiency virus | Reaction or nonreactive | 1 CLIA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Antinuclear antibody | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA, 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Antistreptolysin O | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA, 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Antithrombin III | P- | 8.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Apolipoprotein A1 | BNII | 3 SD | 4 CAP | |
Apolipoprotein A1 | S- | 9.1% | 5 BV | |
Apolipoprotein A1 | 25 mg/dL or 30% | 6 AAB | ||
Apolipoprotein A1 | 0.2 g/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Apolipoprotein AI | 10% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Apolipoprotein b | BNII | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Apolipoprotein B | S- | 11.6% | 5 BV | |
Apolipoprotein B | 20 mg/dL or 25% | 6 AAB | ||
Apolipoprotein B | 0.2 g/L, 10% | 7 RCPA | ||
Apolipoprotein B | 12% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Apolipoprotein B100 | BNII | not evaluated | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ascorbic Acid | S- | 29.9% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Aso-Antistreptolysin | BNII | 2 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Aspartate aminotransferase | S- | 15.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Aspartate Aminotransferase | 20% | 6 AAB | ||
Aspartate Aminotransferase | 20% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Aspartate aminotransferase (AST, SGOT) | +/- 20% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
AST | AU640 | 20% | 4 CAP | |
AST | 8 U/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Automated Differential | 3SD | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
b-Carotene | S- | 43% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
b-Globulins | S- | 11.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
b2-Microglobulin | S- | 9% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Barbituates | 20% or 2 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Barbiturate | Abbott AxSym | 80% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Barbiturates | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Basophile, count | S- | 38.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Benzodiazepine | 20% or 2 SD | 3 NYS | ||
Benzodiazepine | Abbott AxSym | 80% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Benzodiazepines | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Benzoylecgonine | 20% or 2 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Beta 2 microglobulin | 0.06 mg/L or 30% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Beta Carotene | 0.2 umol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Beta-2 Microglobulin | 0.2 mg/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Beta-Hydroxybutyric Acid | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bicarbonate | 2.0 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bicarbonate (Total CO2) | 4 mEq/L or 20% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bilirubin - Direct | 50% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bilirubin - Neonatal | 31% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bilirubin - Total | 5 umol/L, 10% | 7 RCPA | ||
Bilirubin - Total | 31% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bilirubin conjugated | S- | 44.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bilirubin Conjugated | 10 umol/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bilirubin total | S- | 31.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bilirubin, Direct | AU640 | 20% or 0.4 mg/dL (greater) | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bilirubin, Total | AU640 | 20% or 0.4 mg/dL (greater) | 4 CAP | |
Bilirubin, Total | 0.4 mg/dL or 20% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bilirubin, total | +/- 0.4 mg/dL or +/- 20% (greater) | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bilirubin, Urine (qual) | 80% Agreement | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bilirubin,direct | 0.4 mg/dL or 20% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bilirubin,Neonatal | 0.4 mg/dL or 20% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Blood gas p02 | +/- 3 SD | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Blood gas pCO2 | +/- 5 mm Hg or +/- 8% (greater) | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Blood gas pH | +/- 0.04 | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Blood lead | +/- 10% or +/- 4 mcg/dL (greater) | 1 CLIA, 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
BNP | 2.0 SD | 2 WLSH | ||
BNP | Centaur | not evaluated | 4 CAP | |
BNP | 5.0 pg/mL or 20% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
BPb: | +/-4 µg/dL (values <40µg/dL) or +/-10% (values >40µg/dL) | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Bright CD45-/CD14+ | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
C Peptide | S- | 11.7% | 5 BV | |
C Peptide | 1.0 nmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
C-Propeptide type I procollagen | S- | 11.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
C-Reactive protein | S- | 68.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
C-Telopeptide type I procollagen | S- | 14.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
C3 Complement | BNII | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
C3 complement | S- | 8.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
C4 Complement | BNII | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
C4 complement | S- | 16% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CA 125 | 2 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CA 125 antigen | S- | 38.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CA 15-3 | 2 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CA 15.3 antigen | S- | 15.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CA 19-9 | 2 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CA 19.9 antigen | S- | 44.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CA 549 antigen | S- | 16.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CA-125 | 9 U/mL or 30% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CA125 | +/- 3 SD | 3 NYS | ||
CA125 | 20 kU/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CA15-3 | +/- 3 SD | 3 NYS | ||
CA15-3 | 3 kU/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CA19-9 | +/- 3 SD | 3 NYS | ||
CA19-9 | 3 kU/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CA27.29 | +/- 3 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Caffeine | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Calcitonin | 2 ng/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Calcium | AU640 | 1 mg/dL | 4 CAP | |
Calcium | S- | 2.4% | 5 BV | |
Calcium | U- | 1.0 mg/dL | 6 AAB | |
Calcium | 1.0 mg/dL | 6 AAB | ||
Calcium | 0.10 mmol/L | 7 RCPA | ||
Calcium | 8% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Calcium - Ionized | 10% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Calcium - urine | U- | 1 mg/dL | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Calcium, concentration, 24h | U- | 34.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Calcium, Ionized | Radiometer 725 | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Calcium, ionized | U- | 2.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Calcium, output, 24h | U- | 31% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Calcium, total | +/- 1.0 mg/dL | 1 CLIA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Calcium, urine | U- | AU640 | 31% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Calcium-Urine | U- | 0.20 mmol/L | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cannabinoid | Abbott AxSym | 80% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cannabinoids | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Carbamazepine | +/- 25% | 1 CLIA, 2 WLSH, 6 AAB | ||
Carbamazepine | +/- 15% | 3 NYS | ||
Carbamazepine | Abbott AxSym | 25% | 4 CAP | |
Carbamazepine | 2.0 umol/L, 10% | 7 RCPA | ||
Carbamazepine | 25% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Carbamazepine, free | TDX | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Carbohydrate deficient transferrin | S- | 15.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Carbon Dioxide | 5.0 mmol/L | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Carboxyhemoglobin | 3 SD | 2 WLSH | ||
Carboxyhemoglobin | Radiometer 725 | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Carcinoembryonic antigen | S- | 21.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Carcinoembryonic Antigen | 1.2 ng/mL or 30% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CD19+ | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CD2+ | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CD20+ | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CD3+ | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CD3+/CD4+ | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CD3+/CD8+ | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CD3-/CD16+56+ | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CD4+ | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CD5+ | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CD8+ | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CEA | 1.2 ng/mL or 30% | 2 WLSH | ||
CEA | +/- 3 SD | 3 NYS | ||
CEA | Abbott AxSym | 3 SD | 4 CAP | |
CEA | 2.0 ug/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cell identification | 90% or greater consensus on identification | 1 CLIA, 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ceruloplasmin | BNII | 3 SD | 4 CAP | |
Ceruloplasmin | S- | 7.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Chloride | +/- 5% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Chloride | Radiometer 725 | 5% | 4 CAP | |
Chloride | AU640 | 5% | 4 CAP | |
Chloride | S- | 1.5% | 5 BV | |
Chloride | 3.0 mmol/L | 7 RCPA | ||
Chloride | 5% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Chloride -urine | U- | 5% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Chloride, urine | U- | AU640 | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Chloride-Sweat | Sweat | 2 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Chloride-Urine | U- | 2.0 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cholesterol | AU640 | 10% | 4 CAP | |
Cholesterol | S- | 9% | 5 BV | |
Cholesterol | 0.50 mmol/L, 5% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cholesterol - HDL | 11% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cholesterol - LDL | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cholesterol - Total | 9% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cholesterol, high dens. lipoprotein | +/- 30% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cholesterol, total | +/- 10% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cholesterol, Total | 10% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cholesterol,LDL | 30% | 2 WLSH | ||
Cholesterol,LDL | Non-graded analyte | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cholinesterase | S- | 8.9% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cholinesterase, catalitic activity | S- | 7.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CK, Total | AU640 | 30% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ck-MB | Centaur | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CK-MB | 6 U/L & ug/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CK-MB Activity | 40% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CK-MB Mass | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CK-MB qualitative | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CK2 Isoenzyme (CKMB) | 3SD | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CO2 | AU640 | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CO2 - Total | 20% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CoaguChek Prothrombin Time | 15% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cocaine Metab | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cocaine-Metabolite | Abbott AxSym | 80% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Complement C3 | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Complement C4 | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Conjugated Bilirubin, Neonatal | 10 umol/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Copper | S- | 7.7% | 5 BV | |
Copper | P- | 11.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cortisol | +/- 25% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Cortisol | Centaur | 25% | 4 CAP | |
Cortisol | S- | 29.8% | 5 BV | |
Cortisol | 30 nmol/L, 15% | 7 RCPA | ||
Cortisol | 30% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
cPSA | +/- 3 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatine kinase | +/- 30% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Creatine kinase | S- | 30.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatine Kinase | 30% | 6 AAB | ||
Creatine Kinase | 15 U/L, 15% | 7 RCPA | ||
Creatine Kinase | 30% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatine kinase isoenzymes | MB elevated (present or absent) or Target value +/- 3 SD | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatine kinase MB, % | S- | 16.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatine kinase MB, activity | S- | 24.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatine kinase MB, mass | S- | 31.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatinine | +/- 0.3 mg/dL or +/- 15% (greater) | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Creatinine | AU640 | 15% or 0.3 mg/dL (greater) | 4 CAP | |
Creatinine | S- | 6.9% | 5 BV | |
Creatinine | 0.01 mmol/L, 10% | 7 RCPA | ||
Creatinine | 25% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatinine - quantitative, Urine | 0.3 mg/dL or 17% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatinine - semi quant, Urine | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatinine clearence | Patient- | 16% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatinine, concentration | U- | 28.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatinine, output | U- | 15.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatinine, urine | U- | AU640 | 17% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Creatinine-Urine | U- | 0.5 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CRP | BNII | 2 SD | 4 CAP | |
CRP | 0.4 mg/dL or 3 SD% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cryptococcus neoformans Antigen | Positive or Negative or +/- 2 dilutions | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
CSF Protein | AU640 | 2 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cyclosporine | TDX | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Cystein | P- | 8.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
D-Dimer | 30% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
d-Dimer (interpretation) | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
d-Dimer (quantitative) | 2 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
d-Dimer (semi-quantitative) | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Dehydroepiandrosterone sulfate | S- | 22.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Deoxipyridinoline/creatinine, 24h | U- | 21.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Deoxipyridinoline/creatinine, morning sp | U- | 33% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Desipramine | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
DHEA Sulfate | 2.5 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
DHEA Sulphate | 1.0 umol/L, 10% | 7 RCPA | ||
DHEA Sulphate | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Digoxin | +/- 20% or 0.2 ng/mL (greater) | 1 CLIA, 2 WLSH, 6 AAB | ||
Digoxin | 15% or 0.2 ng/mL | 3 NYS | ||
Digoxin | Centaur | 20% or 0.2 ng/mL (greater) | 4 CAP | |
Digoxin | 0.2 nmol/L, 10% | 7 RCPA | ||
Digoxin | 25% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Dipeptidyl-peptidase IV | P- | 10.9% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Direct Bilirubin | 0.4 mg/dL or 20% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Disopyramide | 2.0 umol/L, 10% | 7 RCPA | ||
Disopyramide | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
DMF | 0.45 mmol/L or 30% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Dopamine | 0.25 umol/day, 25% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
DPD (Free)-Urine | U- | 15 nmol/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
DPD (Total)-Urine | U- | 15 nmol/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Elastase-Pl | P- | 16.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Eosinophils, count | B- | 37.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
EP: | +/-6 µg/dL (values <40µg/dL) or +/-15% (values >40µg/dL) | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Erythrocites, count | B- | 4.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Erythrocyte count | +/- 6% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Erythrocyte Sedimentation Rate (ESR) | 3SD | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Erythrocyte Sedimentation Rate (ESR) - Rapid | 3SD | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Erythrocytes | 6% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Estradiol | 3 ng/mL or 30% | 2 WLSH | ||
Estradiol | +/-25% or 30 pg/mL | 3 NYS | ||
Estradiol | U- | 27% | 5 BV | |
Estradiol | 3 pg/mL or 30% | 6 AAB | ||
Estradiol | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Estriol | 2.5 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Estriol - Total | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Estriol - Unconjugated | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Estrogen | 2.5 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ethanol | 20% or 2 SD | 3 NYS | ||
Ethanol | Abbott AxSym | 80% consensus | 4 CAP | |
Ethanol | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ethanol, Blood | HP GLC | 25% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ethanol, Urine | HP GLC | 25% or 9 mg/dL (greater) | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ethosuximide | +/- 20% | 1 CLIA, 2 WLSH | ||
Ethosuximide | +/- 15% | 3 NYS | ||
Ethosuximide | 3 umol/L, 10% | 7 RCPA | ||
Ethosuximide | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Factor VII coagulation | P- | 10.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Factor VIII coagulation | P- | 8.9% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Faecal Percent Dry Weight | 1, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Faecal Total Porphyrin | 15 umol/kg, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Fentanyl | 20% or 2 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ferritin | 4.5 ng/mL or 30% | 2 WLSH | ||
Ferritin | Centaur | 3 SD | 4 CAP | |
Ferritin | 4.5 ng/mL or 30% | 6 AAB | ||
Ferritin | 6.0 ug/L, 15% | 7 RCPA | ||
Ferritin | 19.3% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ferritine | S- | 17.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Fibrinogen | +/- 20% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Fibrinogen | P- | 13.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Folate | 0.9 ng/mL or 30% | 2 WLSH | ||
Folate | S- | 39% | 5 BV | |
Folate | (B)Erthry- | 26.7% | 5 BV | |
Folate | 0.9 ng/mL or 30% | 6 AAB | ||
Folate | 1.0 umol/day, 30% | 7 RCPA | ||
Folate | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Folate, Serum | Centaur | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Folic Acid | +/- 30% or 2.0 ng/mL | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Follicle stimulating hormone | S- | 16.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Follicle Stimulating Hormone | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Follicle-Stimulating Hormone | 2 mIU/mL or 25% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
fPSA | +/- 3 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Fractional Carboxyhemoglobin | 0.02 | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Fractional Methemoglobin | 1.0, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Fractional Oxyhemoglobin | 3, 4% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Free Estriol | +/-25% or 3.0 ng/mL | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Free phenytoin | +/- 20% | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Free PSA | 1.5 ug/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Free T3 | 3 SD | 2 WLSH | ||
Free T3 | 3.0 pmol/L | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Free T4 (Endocrinology) | 1.5 pmol/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Free T4 (General Chemistry) | 3 pmol/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Free thyroxine | +/- 3 SD | 1 CLIA, 2 WLSH, 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Free thyroxine (FT4) | S- | 9.9% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Fructosamine | S- | 4.5% | 5 BV | |
Fructosamine | 30 umol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
FSH | +/-25% | 3 NYS | ||
FSH | Centaur | 3 SD | 4 CAP | |
FSH | 4.0 IU/L, 20% | 7 RCPA | ||
FSH | 2 mIU/mL or 25% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
g-Globulins | S- | 16.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
g-glutamyltransferase | S- | 22.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Galactosy hydroxylisine | S- | 16.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Gamma glutamyltransferase | +/- 30% | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Gamma-glutamyl transferase [GGT] | 20% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
gamma-Glutamyl-transferase | 10 IU/L or 20% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Gamma-Glutamyltransferase | 30% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Gastrin | 25 pmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Gentamicin | +/- 25% | 1 CLIA, 2 WLSH, 6 AAB | ||
Gentamicin | +/- 15% | 3 NYS | ||
Gentamicin | Abbott AxSym | 25% | 4 CAP | |
Gentamicin | 0.5 mg/L, 10% | 7 RCPA | ||
Gentamicin | 20% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
GGT | AU640 | 3 SD | 4 CAP | |
GGT | 8 U/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Globulins, total | S- | 8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glucose | +/- 6 mg/dL or +/- 10% (greater) | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Glucose | Radiometer 725 | 10% or 6 mg/dL (greater) | 4 CAP | |
Glucose | AU640 | 10% or 6 mg/dL (greater) | 4 CAP | |
Glucose | S- | 6.3% | 5 BV | |
Glucose | 0.5 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glucose (GLUC ) | 0.3 mmol/L, 8.0% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glucose -urine | U- | 10% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glucose, CSF | 10% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glucose, Urine | AU640 | 10% or 6 g/24 hs (greater) | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glucose, Urine (qual) | 80% Agreement | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glucose, Whole Blood | 20 mg/dL or 20% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glucose-6-phosphate-1-dehydrogenase | (B)Erythr- | 38.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glucose-Blood Gas | BG | 1.0 mmol/day, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glucose-CSF | CSF | 1.0 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glucose-Urine | U- | 1.0 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glutathione peroxidase | S- | 11.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glycated albumin | S- | 7.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glycated Hemoglobin A1c | 9% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glycated total protein | S- | 3.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Glycohemoglobin | 1.00% or 25% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Growth Hormone | 2 mU/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Haptoglobin | BNII | not evaluated | 4 CAP | |
Haptoglobin | P, S- | 27.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
hCG | 32% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
hCG (Maternal Sera) | +/- 3 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
hCG, Quant | Centaur | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
hCG,qualitative (serum) | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
hCG-quantitative | 3.0 IU/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
hCG-quantitative-Urine | U- | 5 IU/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
HDL 1 cholesterol | S- | 11.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
HDL 2 cholesterol | S- | 23.9% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
HDL 3 cholesterol | S- | 9.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
HDL cholesterol | S- | 11.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
HDL Cholesterol | 30% | 6 AAB | ||
HDL Cholesterol | 0.20 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
HDL- Cholesterol | AU640 | 30% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hematocrit | +/- 6% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Hematocrit | B- | 4.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hemoglobin | +/- 7% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Hemoglobin | B- | 4.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hemoglobin A1 C | S- | 4.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hemoglobin A1c | 1.0 or 25% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hemoglobin A1C | 0.5, 5% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hemoglobin concentration | 3 g/L, 3% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hemoglobin, Urine (qual) | 80% Agreement | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hemoglobin,total | 7% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hemoglobin,Total A1 | 1.0 or 25% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hepatitis (Anti-HBc HBsAg HBeAg Anti-HCV ) | Reactive (Positive) or Nonreactive (Negative) | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hepatitis (HBsAg, anti-HBc, HBeAg) | Reactive (positive) or nonreactive (negative) | 1 CLIA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Heterophile | Positive or Negative or +/- 2 dilutions | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
high sensitivity CRP | 0.4 mg/L or 3 SD% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
HMMA | 20 umol/day, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Homocysteine | Non-graded analyte | 3 NYS | ||
Homocysteine | IMX | 3 SD | 4 CAP | |
Homocysteine | P- | 17.7% | 5 BV | |
Homocysteine | 2.5 umol/L or 20% | 6 AAB | ||
Homocysteine | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
hS-CRP | 2.0 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
hs-CRP | BNII | not evaluated | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Human Chorionic Gonadotropin | 3SD | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Human chorionic gonadotropin | +/- 3 SD or (positive or negative) | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
HVA | 8 umol/day, 25% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hydroxiproline/creatinine | S- | 32.9% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hydroxiproline/minute, night urine | U- | 43% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Hydroxyproline-Urine | U- | 10 umol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
IBC - Total | 25% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
IBC - Unsaturated | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
IgA | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
IgA, Blood | BNII | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
IgB | +/- 3 SD | 1 CLIA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
IgE | +/- 3 SD | 3 NYS | ||
IgE | 3SD | 6 AAB | ||
IgE | Opt | 3SD | 6 AAB | |
IgE | 4.0 IU/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
IGF-1 | 3 nmol/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
IgG | +/- 25% | 1 CLIA, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
IgG, Blood | BNII | 25% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
IgG-Blood | BNII | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
IgG-CSF | BNII | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
IgM | +/- 3 SD | 1 CLIA, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
IgM, Blood | BNII | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Imipramine | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Immunofix Urine | Sebia Hydrasis LS | 90% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Immunofixation Serum | Sebia Hydrasis LS | 90% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Immunoglobin G-CSF | CSF | 0.1 g/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Immunoglobulin A | S- | 13.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Immunoglobulin G | S- | 8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Immunoglobulin M | S- | 16.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Immunoglobulins K chain | S- | 8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Immunoglobulins l chain | S- | 8.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Infectious mononucleosis | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
INR | 2 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Insulin | +/-25% or 3.0 uU/mL | 3 NYS | ||
Insulin | S- | 32.9% | 5 BV | |
Insulin | 5 mU/L, 25% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Interferon receptor | (B)Leuc- | 17.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Interleukin-1B | S- | 36.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Interleukin-8 | S- | 29.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ionised Calcium | 0.05 mmol/L | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ionized Calcium | 0.13 mmol/L | 2 WLSH | ||
Ionized Calcium | 0.25 mmol/L | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Iron | AU640 | 20% | 4 CAP | |
Iron | (B)Leuc- | 30.7% | 5 BV | |
Iron | 20% | 6 AAB | ||
Iron | 5 umol/L | 7 RCPA | ||
Iron | 31% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Iron binding capacity | 20% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Iron Binding Capacity | AU640 | 20% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Iron Saturation | Calculated | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Iron, total | +/- 20% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Isopropanol | HP GLC | not evaluated | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Ketones, Urine (qual) | 80% Agreement | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lactate | 0.2 mmol/L or 2SD | 2 WLSH | ||
Lactate | Radiometer 725 | 4 CAP | ||
Lactate | AU640 | 2 SD | 4 CAP | |
Lactate | B- | 30.4% | 5 BV | |
Lactate | 1.0 mmol/L, 10% | 7 RCPA | ||
Lactate | 1.0 mmol/day, 10% | 7 RCPA | ||
Lactate | 30% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lactate Dehydrogenase | AU640 | 20% | 4 CAP | |
Lactate Dehydrogenase | 20% | 6 AAB | ||
Lactate Dehydrogenase | 30 U/L, 15% | 7 RCPA | ||
Lactate Dehydrogenase | 20% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lactate dehydrogenase (LDH) | +/- 20% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Lactate dehydrogenase (LDH) | S- | 11.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lactate dehydrogenase 1 isoform (LDH1) | S- | 8.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lactate dehydrogenase 2 isoform (LDH2) | S- | 5.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lactate dehydrogenase 3 isoform (LDH3) | S- | 5.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lactate dehydrogenase 4 isoform (LDH4) | S- | 11% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lactate dehydrogenase 5 isoform (LDH5) | S- | 14.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lactate-CSF | CSF | 0.1 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lactoferrin | P- | 16.4% | 5 BV | |
Lactoferrin | Opt | 0.5 mg/mL or 20% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
LD Isoenzymes 3-5 | 3.00% or 30% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
LDH isoenzymes | LDH1/LDH2 (+ or -) or Target value +/- 30% | 1 CLIA, 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
LDL Cholesterol | S- | 13.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
LDL Cholesterol (Direct) | 15 mg/dL or 20% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
LDL receptor mRNA | S- | 24.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
LDL- Cholesterol | AU640 | 20% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lead, Blood | Spectra AA | 10% or 4 ug/dL (greater) | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Leukocyte count | +/- 15% | 1 CLIA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Leukocytes | 15% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Leukocytes, count | P- | 14.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
LH | 2.5 SD | 2 WLSH | ||
LH | +/-25% or 1.5 IU/L | 3 NYS | ||
LH | Centaur | 3 SD | 4 CAP | |
LH | 2.0 IU/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lignocaine | 2.0 umol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lipase | 30% | 2 WLSH | ||
Lipase | AU640 | 30% | 4 CAP | |
Lipase | S- | 29.1% | 5 BV | |
Lipase | 30% | 6 AAB | ||
Lipase | 40 U/L, 20% | 7 RCPA | ||
Lipase | 37% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lipoprotein (a) | S- | 28.8% | 5 BV | |
Lipoprotein (a) | 10 mg/dL or 30% | 6 AAB | ||
Lipoprotein (a) | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lithium | +/- 20% or 0.3 mmol/L | 1 CLIA, 2 WLSH, 6 AAB | ||
Lithium | +/- 15% or 0.3 mmol/L | 3 NYS | ||
Lithium | AVL 9180 | 20% or 0.3 mEq/L (greater) | 4 CAP | |
Lithium | 0.2 mmol/L | 7 RCPA | ||
Lithium | 10% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Luteinizing hormone | S- | 19.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Luteinizing Hormone | 2 mIU/mL or 25% | 6 AAB | ||
Luteinizing Hormone | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Lymphocytes, count | B- | 16% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
M-Protein Interpr. | Sebia Hydrasis LS | 90% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Magnesium | +/- 25% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Magnesium | AU640 | 25% | 4 CAP | |
Magnesium | S- | 4.8% | 5 BV | |
Magnesium | (B)Leuc- | 21.2% | 5 BV | |
Magnesium | (B)Erythr- | 7.8% | 5 BV | |
Magnesium | 3 mmol/L | 7 RCPA | ||
Magnesium | 0.1 mmol/L, 12% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Magnesium (serum) | U- | 0.12 mmol/L | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Magnesium - Ionized | 10% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Magnesium - urine | U- | 25% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Magnesium, concentration, 24h | U- | 52.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Magnesium, ionized | U- | 2.9% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Magnesium, output, 24h | U- | 45% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Magnesium, urine | U- | AU640 | 25% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
MCV | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Mean corpuscular hemoglobin (HCM) | (B)Erythr- | 2.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Mean corpuscular hemoglobin concentratio | (B)Erythr- | 2.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Mean corpuscular volume (MCV) | (B)Erythr- | 2.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Mean platelet volume (MPV) | (B)Plat- | 5.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Metanephrine | 0.5 umol/day, 33% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Methadone | Pos/Neg | 2 WLSH | ||
Methadone | 20% or 2 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Methanol | HP GLC | not evaluated | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Methemoglobin | 3 SD | 2 WLSH | ||
Methemoglobin | Radiometer 725 | 2% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Methotrexate | 0.1 umol/L, 10% | 7 RCPA | ||
Methotrexate | 25% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Methqualone | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Microalbumin - quantitative | 2.5 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Microalbumin, urine | U- | AU640 | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Monocytes, count | B- | 27.9% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
MSAFP | Centaur | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
MShCG | Centaur | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Mucinous carcinoma-associated antigen (M | S- | 18.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Myoglobin | S- | 19.6% | 5 BV | |
Myoglobin | 15 ng/mL or 30% | 6 AAB | ||
Myoglobin | 30% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Myoglobin - qualitative | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Myoglobin - quantitative | 2 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
N-Acetyl Glucosaminidase, concentration, | U- | 53.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
N-Acetyl Glucosaminidase, output | U- | 46.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
N-acetyl procainamide | +/- 15% | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
N-acetylprocainamide | Abbott AxSym | 25% | 4 CAP | |
N-acetylprocainamide | 20% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
N-Telopeptides-Urine | U- | 80 nmolBCE/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Napa | Abbott AxSym | 25% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Neutrophyles, count | B- | 22.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Nitrogen, output | U- | 18.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Noradrenaline | 50 nmol/day, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Normetanephrine | 1.0 umol/day, 33% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Nortriptyline | 10 nmol/L, 10% | 7 RCPA | ||
Nortriptyline | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
NSE | 2.0 ug/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Oestradiol | 100 pmol/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Oestriol(total) | 20 nmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Oestriol(unconjugated) | 5 nmol/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Oligoclonal Bands | Sebia Hydrasis LS | 90% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Opiate | Abbott AxSym | 80% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Opiates | Pos/Neg | 2 WLSH | ||
Opiates | 20% or 2 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Osmolality | Freezing point | 2 SD | 4 CAP | |
Osmolality | S- | 1.5% | 5 BV | |
Osmolality | U- | 9. mOsm/kg or 10% | 6 AAB | |
Osmolality | 8 mmol/kg | 7 RCPA | ||
Osmolality | 3% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Osmolality, urine | U- | Freezing point | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Osmolality,serum | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Osmolality,urine | U- | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Osmolality-Urine | U- | 6 mmol/kg, 2% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Osteocalcin | S- | 11.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Oxalate, concentration | U- | 48.2% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Oxalate, output | U- | 46.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Oxyhemoglobin | 3 SD | 2 WLSH | ||
Oxyhemoglobin | Radiometer 725 | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
PAP | 2.5 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Paracetamol | 20 umol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Partial thromboplastin time | +/- 15% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
pCO2 | Radiometer 725 | 8% or 5 mm Hg (greater) | 4 CAP | |
pCO2 | B- | 5.7% | 5 BV | |
pCO2 | 5.0 mm Hg or 8% | 6 AAB | ||
pCO2 | 2.0 mm Hg, 8% | 7 RCPA | ||
pCO2 | 5 kPa, 8% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
pH | Radiometer 725 | 0.04 | 4 CAP | |
pH | 0.04 | 6 AAB | ||
pH | 0.04 | 7 RCPA | ||
pH | 0.04 | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
pH [H+] | B- | 3.9% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
pH, Urine (qual) | 80% Agreement | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
pH,Fluid | Corning 445 pH meter | 0.04 | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phencyclidine | Pos/Neg | 2 WLSH | ||
Phencyclidine | 20% or 2 SD | 3 NYS | ||
Phencyclidine | Abbott AxSym | 80% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phenobarbital | +/- 20% | 1 CLIA, 2 WLSH, 6 AAB | ||
Phenobarbital | +/- 15% | 3 NYS | ||
Phenobarbital | Abbott AxSym | 20% | 4 CAP | |
Phenobarbital | 20% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phenobarbitone | 3.0 umol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phenytoin | +/- 25% | 1 CLIA, 2 WLSH, 6 AAB | ||
Phenytoin | +/- 15% | 3 NYS | ||
Phenytoin | Abbott AxSym | 25% | 4 CAP | |
Phenytoin | 3.0 umol/L, 10% | 7 RCPA | ||
Phenytoin | 25% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phenytoin, free | TDX | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phosphate | S- | 10.2% | 5 BV | |
Phosphate | 0.1 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phosphate tubular reabsorption | Patient- | 3.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phosphate, concentration | U- | 31.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phosphate, output | U- | 22.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phosphate-Urine | U- | 2.5 mmol/L | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phospholipids | S- | 8.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phosphorus | 0.5 mg/dL or 12% | 2 WLSH | ||
Phosphorus | +/- 0.45 mg/dL or 13% | 3 NYS | ||
Phosphorus | AU640 | 10.7% or 0.3 mg/dL (greater) | 4 CAP | |
Phosphorus | U- | 3. mg/dL or 15% | 6 AAB | |
Phosphorus | 0.4 mg/dL or 15% | 6 AAB | ||
Phosphorus | 12% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phosphorus -urine | U- | 0.5 mg/dL or 12% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Phosphorus, urine | U- | AU640 | 23% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Plasma Renin Activity | 1.0 ng/mL/hr, 25% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Plasma Total Porphyrin | 3 nmol/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Platelet count | +/- 25% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Platelet, count | B- | 13.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Platelets | 25% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
pO2 | Radiometer 725 | 3 SD | 4 CAP | |
pO2 | 3SD | 6 AAB | ||
pO2 | 5 mm Hg, 5% | 7 RCPA | ||
pO2 | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Polylysine | 45 mmol/L or 30% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Potassium | +/- 0.5 mmol/L | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Potassium | Radiometer 725 | 0.5 mmol/L | 4 CAP | |
Potassium | S- | 5.8% | 5 BV | |
Potassium | (B)Leuc- | 16% | 5 BV | |
Potassium | 0.2 mmol/L | 7 RCPA | ||
Potassium | 6% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Potassium - urine | U- | 2 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Potassium, concentration | U- | 31.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Potassium, output | U- | 28.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Potassium, urine | U- | AU640 | 29% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Potassium-POCT | POCT | 2.0 mmol/L | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Potassium-Urine | U- | 2.0 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Potassium` | AU640 | 0.5 mmol/L | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Pre-albumin | 2.5 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Prealbumin | BNII | 25% or 5 mg/dL (greater) | 4 CAP | |
Prealbumin | S- | 14.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Pregnancy, Serum | pos/neg | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Primidone | +/- 25% | 1 CLIA, 2 WLSH, 6 AAB | ||
Primidone | +/- 15% | 3 NYS | ||
Primidone | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Procainamide | +/- 15% | 3 NYS | ||
Procainamide | Abbott AxSym | 25% | 4 CAP | |
Procainamide | 25% | 6 AAB | ||
Procainamide | 20% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Procainamide (and metabolite) | +/- 25% | 1 CLIA, 2 WLSH, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Procainamide, N-Acetyl (NAPA) | 25% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Procollagen type 1 N-terminal | S- | 10.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Progesterone | 300 pg/mL or 30% | 2 WLSH | ||
Progesterone | +/-25% or 1.0 ng/mL | 3 NYS | ||
Progesterone | Centaur | 3 SD | 4 CAP | |
Progesterone | 0.3 ng/mL or 30% | 6 AAB | ||
Progesterone | 2 nmol/L, 25% | 7 RCPA | ||
Progesterone | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Prolactin | 3.6 ng/mL or 30% | 2 WLSH | ||
Prolactin | +/-25% or 1.0 ug/L | 3 NYS | ||
Prolactin | Centaur | 3 SD | 4 CAP | |
Prolactin | 3.6 ng/mL or 30% | 6 AAB | ||
Prolactin | 20 mU/L, 20% | 7 RCPA | ||
Prolactin | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Prolactin (men) | S- | 21.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Prolyl endopeptidase | P- | 19.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Propoxyphene | Pos/Neg | 2 WLSH | ||
Propoxyphene | 20% or 2 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Prostate-Specific Antigen | 0.9 ng/mL or 30% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Prostatic specific antigen (PSA) | S- | 30% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein | 10% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein (Total) | 5.0 g/L | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein - Total | 6% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein C | S- | 18.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein El. Interpr, Serum | Sebia Hydrasis LS | 90% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein El. Interpr, Ur 24 | Sebia Hydrasis LS | 90% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein El. Interpr, Urine | Sebia Hydrasis LS | 90% consensus | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein S | P- | 20.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein, concentration | U- | 43.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein, output | U- | 40% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein, Total | AU640 | 10% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein, total | S- | 3.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein, Urine (qual) | 80% Agreement | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Protein,total - urine | U- | 10% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Prothrombin time | +/- 15% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Prothrombin time | P- | 5.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Prothrombin Time (PT) | 15% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
PSA | 0.9 ng/mL or 30% | 2 WLSH | ||
PSA | +/- 3 SD | 3 NYS | ||
PSA | Abbott AxSym | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
PSA - free | 0.9 ng/mL or 30% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
PTH | Centaur | 3 SD | 4 CAP | |
PTH | 2.5 pmol/L, 25% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Pyridinoline/creatinine, morning spot | U- | 12.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Pyruvate | B- | 17.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Qualitative hCG | Positive or Negative | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Quinidine | +/- 25% | 1 CLIA, 2 WLSH, 6 AAB | ||
Quinidine | +/- 15% | 3 NYS | ||
Quinidine | Abbott AxSym | 25% | 4 CAP | |
Quinidine | 2.0 umol/L, 10% | 7 RCPA | ||
Quinidine | 25% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
RBC Folate | 2.5 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
RBC Total Porphyrin | 0.3 umol/L rc, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Red cell distribution wide | B- | 4.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Reticulocyte Count | 0.50% or 30% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Reticulocyte highly fluorescent, count | S- | 24% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Reticulocyte low fluorescent, count | S- | 2.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Reticulocyte medium fluorescent, count | S- | 19.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Reticulocyte, count | S- | 16.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Reticulocytes | 3 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Retinol | S- | 18.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Rheumatoid factor | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA | ||
Rheumatoid factor | S- | 13.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Rheumatoid Factor | Positive or Negative or +/- 2 dilutions | 3 NYS | ||
Rheumatoid Factor | BNII | 2 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Rubella | Target value +/- 2 dilution or (pos. or neg.) | 1 CLIA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Salicylate | 25% | 2 WLSH | ||
Salicylate | +/- 15% | 3 NYS | ||
Salicylate | 0.1 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Salicylates | AU640 | 3 SD | 4 CAP | |
Salicylates | 25% | 6 AAB | ||
Salicylates | 20% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
SCC antigen | S- | 45.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sedimentation Rate [ESR] | 2.5 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Selenium | B- | 14.5% | 5 BV | |
Selenium | P- | 14.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Serotonin | 0.3 umol/day, 30% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sex hormone binding globulin (SHBG) | S- | 21.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
SHBG | 5 nmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sickle Cell Screen | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sodium | +/- 4 mmol/L | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Sodium | Radiometer 725 | 4 mmol/L | 4 CAP | |
Sodium | AU640 | 4 mmol/L | 4 CAP | |
Sodium | S- | 0.9% | 5 BV | |
Sodium | (B)Leuc- | 57.7% | 5 BV | |
Sodium | (B)Erythr- | 4.6% | 5 BV | |
Sodium | 3.0 mmol/L | 7 RCPA | ||
Sodium | 4 mmol/L, 5% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sodium - urine | U- | 2 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sodium, concentration | U- | 28.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sodium, output | U- | 32% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sodium, urine | U- | AU640 | 26% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sodium-Sweat | Sweat | 2 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sodium-Urine | U- | 2.0 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Specific Gravity | U- | 0.01 | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Specific gravity, Urine (qual) | 80% Agreement | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sperm Count | 3 million/mL or 25% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sperm Morphology | 5% normal or 20%% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sperm Viability | 5% viable or 20%% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Superoxide dismutase | (B)Erythr- | 13.5% | 5 BV | |
Superoxide dismutase | S- | 19.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Sweat Conductivity | 2 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
T Uptake | 7% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
T3 uptake | +/- 3 SD by method | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
T3 Uptake | Centaur | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
T3, T3 | Centaur | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
T3-uptake | S- | 5.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
T4, Free | Centaur | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
T4, Total | Centaur | 20% or 1 ug/dL (greater) | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Tacrolimus (FK 506) | IMX | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Testosterone | 0.3 ng/mL or 30% | 2 WLSH | ||
Testosterone | +/-25% or 1.0 ng/dL | 3 NYS | ||
Testosterone | Centaur | 3 SD | 4 CAP | |
Testosterone | Saliva- | 22.7% | 5 BV | |
Testosterone | S- | 14% | 5 BV | |
Testosterone | 0.3 ng/mL or 30% | 6 AAB | ||
Testosterone | 0.5 nmol/L, 20% | 7 RCPA | ||
Testosterone | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Testosterone,free | 0.3 ng/mL or 30% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
THC-cannabinoids | 20% or 2 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Theophylline | +/- 25% | 1 CLIA, 2 WLSH, 6 AAB | ||
Theophylline | +/- 15% | 3 NYS | ||
Theophylline | Abbott AxSym | 25% | 4 CAP | |
Theophylline | 3.0 umol/L, 10% | 7 RCPA | ||
Theophylline | 25% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Thyroglobulin | S- | 17.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Thyroid stimulating hormone | +/- 3 SD | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Thyroid Stimulating Hormone | 3SD | 6 AAB | ||
Thyroid Stimulating Hormone | 30% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Thyroid stimulating hormone (TSH) | S- | 24.6% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Thyroxin binding globulin (TBG) | S- | 7.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Thyroxine | +/- 20% or 1.0 mcg/dL (greater) | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Thyroxine | 8 nmol/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Thyroxine (T4) | S- | 8.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Thyroxine - Free | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Thyroxine - Total | 8% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Thyroxine, Free | 3SD | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Thyroxine, Total | 1.0 µg/dL or 20% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
TIBC | Centaur | 20% | 4 CAP | |
TIBC | 10.0 umol/L | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Tissue polypeptide antigen (TPA) | S- | 36.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Tissue polypeptide specific antigen (TPS | S- | 58.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Tobramycin | +/- 25% | 1 CLIA, 2 WLSH, 6 AAB | ||
Tobramycin | +/- 15% | 3 NYS | ||
Tobramycin | Abbott AxSym | 25% | 4 CAP | |
Tobramycin | 0.5 mg/L, 10% | 7 RCPA | ||
Tobramycin | 25% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total Beta hCG | +/- 3 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total Bilirubin, Neonatal | 15 umol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total Carotenoids | 0.4 umol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total catecolamines, concentration, 24h | U- | 29.8% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total Estriol | +/-25% or 3.0 ng/mL | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total Glycated Hemoglobin | 1.2 or 20% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total Iron Binding Capacity (TIBC) | 25% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total protein | +/- 10% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total Protein | U- | 1.0 mg/dL or 25% | 6 AAB | |
Total Protein | 10% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total protein, urine | U- | AU640 | 44% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total Protein-CSF | CSF | 0.1 g/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total Protein-Urine | U- | 0.1 g/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total PSA | 1.5 ug/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total T3 (Endocrinology) | 0.3 nmol/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total T3 (General Chemistry) | 0.3 nmol/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Total T4 | 8 nmol/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Transferrin | 2.5 SD | 2 WLSH | ||
Transferrin | BNII | 20% | 4 CAP | |
Transferrin | S- | 3.8% | 5 BV | |
Transferrin | 0.5 g/L | 7 RCPA | ||
Transferrin | 12% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Tricyclic Antidepressants | Pos/Neg | 2 WLSH | ||
Tricyclic Antidepressants | 20% or 2 SD | 3 NYS | ||
Tricyclic Antidepressants | 10 nmol/L, 10% | 7 RCPA | ||
Tricyclic Antidepressants | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Triglyceride | S- | 27.9% | 5 BV | |
Triglyceride | 0.20 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Triglycerides | +/- 25% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB | ||
Triglycerides | AU640 | 25% | 4 CAP | |
Triglycerides | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Triiodothyronine | +/- 3 SD | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Triiodothyronine (T3) | S- | 11.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Triiodothyronine - Free | 20% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Triiodothyronine - Total | 20% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Triiodothyronine, Free (Free T3) | 1.5 pg/mL or 30% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Triiodothyronine, Total (T3) | 3SD | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Troponin I | Centaur | not evaluated | 4 CAP | |
Troponin I | 0.9 ng/mL or 30% | 6 AAB | ||
Troponin I | 0.2 ng/mL, 10% | 7 RCPA | ||
Troponin I | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Troponin I - qualitative | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Troponin I - quantitative | 2 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Troponin T | 0.1 ng/mL or 30% | 6 AAB | ||
Troponin T | 0.1 ng/mL, 10% | 7 RCPA | ||
Troponin T | 2 SD | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Troponin T - qualitative | Pos/Neg | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Troponin T - quantitative | 2 SD | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
TSH | Centaur | 3 SD | 4 CAP | |
TSH | 0.6 mU/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Tumor Necrosis Factor-a | S- | 48.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
TUptake | 3SD | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
uE3 (Maternal Sera) | +/- 3 SD | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Unsaturated Iron Binding Capacity (UIBC) | 25% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urate | S- | 11.9% | 5 BV | |
Urate | 0.050 mmol/L | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urate, concentration, 24h | U- | 28.7% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urate, output, 24h | U- | 21.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urate-Urine | U- | 0.3 mmol/L | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urea | AU640 | 9% or 2 mg N/dL (greater) | 4 CAP | |
Urea | S- | 15.7% | 5 BV | |
Urea | 0.1 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urea Nitrogen | +/- 2 mg/dL or +/- 9% (greater) | 1 CLIA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urea Nitrogen - urine | U- | 2 mg/dL or 9% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urea, concentration, 24h | U- | 27.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urea, output, 24h | U- | 22.1% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urea, urine | U- | AU640 | 21% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urea-POCT | POCT | 1.0 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urea-Urine | U- | 20 mmol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urea/Urea Nitrogen | 16% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Uric acid | +/- 17% | 1 CLIA, 2 WLSH, 3 NYS, 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Uric Acid | AU640 | 17% | 4 CAP | |
Uric Acid | U- | 17% | 6 AAB | |
Uric Acid | 17% | 6 AAB | ||
Uric Acid | 12% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Uric Acid - urine | U- | 17% | 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Uric acid, urine | U- | AU640 | 24% | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urine ALA | 5 umol/L, 25% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urine Creatinine | U- | 3 mg/dL or 15% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urine Microalbumin | U- | 10 mg/L or 25% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urine Porphobilinogen (Quantitative) | 5 umol/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Urine Total Porphyrin | 15 nmol/L, 15% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Valproate | 25 umol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Valproic acid | +/- 25% | 1 CLIA, 2 WLSH, 6 AAB | ||
Valproic acid | +/- 15% | 3 NYS |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Valproic Acid | Abbott AxSym | 25% | 4 CAP | |
Valproic Acid | 25% | 6 AAB | ||
Valproic Acid | 15% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Valproic Acid, free | TDX | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Vancomycin | 25% | 2 WLSH | ||
Vancomycin | +/- 15% | 3 NYS | ||
Vancomycin | Abbott AxSym | 3 SD | 4 CAP | |
Vancomycin | 1.5 ug/mL or 25% | 6 AAB | ||
Vancomycin | 2.0 mg/L, 10% | 7 RCPA | ||
Vancomycin | 20% | 8 CFX |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Vanilmandelic Acid concentration, 24h | U- | 31.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Vitamin A | 0.3 umol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Vitamin B-12 | Centaur | 3 SD | 4 CAP |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Vitamin B12 | 60 pg/mL or 30% | 2 WLSH | ||
Vitamin B12 | +/- 25% | 3 NYS | ||
Vitamin B12 | 60 pg/mL or 30% | 6 AAB | ||
Vitamin B12 | 20 pmol/L, 20% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Vitamin D3 | 5 nmol/L, 15 | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Vitamin E | 5.0 umol/L, 10% | 7 RCPA |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Von Willebrand factor | P- | 7.4% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Water | S- | 3.3% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
White cell differentiation | Target +/- 3 SD based on percentage of different types of white cells | 1 CLIA, 2 WLSH |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Whole Blood Glucose | 6 mg/dL or 10% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Whole Blood Prothrombin Time | 15% | 6 AAB |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
Zinc | P- | 11% | 5 BV | |
Zinc | S- | 13.5% | 5 BV |
Analyte | Fluid | Method | Limit | Source |
---|---|---|---|---|
ZPP: | +/-15% (µmol/mol heme) | 3 NYS |